GPX4 and nasopharyngeal carcinoma: Indeed, GPX4 knockdown or combined utilization of the low-dose GPX4 inhibitor RSL3 with DDP, 5-FU, or TAX displayed a higher inhibitory effect in EBV-positive NPC cells (Fig. 4E).